読み込み中
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
前日終値
$3.63
−$0.48 · -11.68%
日中の時刻はETです。市場データは遅延する場合があります。
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
日中レンジ
現在 $3.63
52週レンジ
現在 $3.63
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
29
割高
センチメント
51
まちまち
リスク
96
極めて高いリスク
モメンタム
33
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
日中レンジ
現在 $3.63
52週レンジ
現在 $3.63
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 30.16万 USD | 16.87万 USD | 11.07万 USD | 132.14万 USD | 14.41万 USD |
| 売上原価 | 6.14万 USD | 3.66万 USD | 2.57万 USD | 36.32万 USD | 2.14万 USD |
| 粗利益 | 24.03万 USD | 13.21万 USD | 8.51万 USD | 95.81万 USD | 12.26万 USD |
| 研究開発 | 108.35万 USD | 119.1万 USD | 192.2万 USD | 51.1万 USD | 13.9万 USD |
| 販売・一般管理 | 754.76万 USD | 669.59万 USD | 385.95万 USD | 279.12万 USD | 614.12万 USD |
| 営業費用 | 863.12万 USD | 788.68万 USD | 578.14万 USD | 279.12万 USD | 614.12万 USD |
| 受取利息 | 8240 USD | 3193 USD | — | — | — |
| 支払利息 | — | — | 3.88万 USD | 5.94万 USD | 8.23万 USD |
| 減価償却費と償却費 | 2.15万 USD | 1.51万 USD | 4254 USD | 535 USD | 537 USD |
| 営業利益 | −839.09万 USD | −775.46万 USD | −569.63万 USD | −183.3万 USD | −601.86万 USD |
| 純利益 | −822.22万 USD | −760.72万 USD | −464.87万 USD | −169.78万 USD | −607.8万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2026年8月31日 | 1:30 | — | — |
発効済み 2026年8月31日
1:30
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
